Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial
Preprint in Research Square (March 2024)
The most recent citing publications are shown below. View all 34 publications that cite this research output on Dimensions.
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma
Article in Current Drug Targets (December 2023)
Intracranial pressure management in fulminant cerebral oedema after CAR T‐cell therapy: Not all is lost!
Article in British Journal of Haematology (December 2023)